Encorafenib
Encorafenib (LGX818) is a potent and selective oral inhibitor of the BRAF V600E mutation, with an IC50 of 0.3 nM. It is widely used in preclinical oncology research, demonstrating significant antitumor activity in both in vitro cellular assays and in vivo models of melanoma and colorectal cancer.
Product Specifications
CAS Number
1269440-17-6
Product Name Alternative
Raf, Raf kinases, B-Raf (V600E), Inhibitor, LGX 818, LGX818, LGX-818, Encorafenib, inhibit
Field of Research
Pharmacology & Drug Discovery, Signal Transduction
Purity
98.64% (May vary between batches)
Solubility
H2O:< 1 mg/mL (insoluble or slightly soluble) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:9.3 mg/mL (17.22 mM) ; DMSO:257 mg/mL (475.92 mM) ; Ethanol:93 mg/mL (172.22 mM)
Smiles
COC (=O) N[C@@H] (C) CNc1nccc (n1) -c1cn (nc1-c1cc (Cl) cc (NS (C) (=O) =O) c1F) C (C) C
Molecular Formula
C22H27ClFN7O4S
Molecular Weight
540.01
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
